Literature DB >> 7964489

A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit.

M Pizza1, M R Fontana, M M Giuliani, M Domenighini, C Magagnoli, V Giannelli, D Nucci, W Hol, R Manetti, R Rappuoli.   

Abstract

Escherichia coli enterotoxin (LT) and the homologous cholera toxin (CT) are A-B toxins that cause travelers' diarrhea and cholera, respectively. So far, experimental live and killed vaccines against these diseases have been developed using only the nontoxic B portion of these toxins. The enzymatically active A subunit has not been used because it is responsible for the toxicity and it is reported to induce a negligible titer of toxin neutralizing antibodies. We used site-directed mutagenesis to inactivate the ADP-ribosyltransferase activity of the A subunit and obtained nontoxic derivatives of LT that elicited a good titer of neutralizing antibodies recognizing the A subunit. These LT mutants and equivalent mutants of CT may be used to improve live and killed vaccines against cholera and enterotoxinogenic E. coli.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7964489      PMCID: PMC2191794          DOI: 10.1084/jem.180.6.2147

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  40 in total

1.  An oral B subunit: whole cell vaccine against cholera.

Authors:  J Holmgren; A M Svennerholm; M Jertborn; J Clemens; D A Sack; R Salenstedt; H Wigzell
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

2.  The crystal structure of diphtheria toxin.

Authors:  S Choe; M J Bennett; G Fujii; P M Curmi; K A Kantardjieff; R J Collier; D Eisenberg
Journal:  Nature       Date:  1992-05-21       Impact factor: 49.962

3.  Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine.

Authors:  H Peltola; A Siitonen; H Kyrönseppä; I Simula; L Mattila; P Oksanen; M J Kataja; M Cadoz
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

4.  Research priorities for diarrhoeal disease vaccines: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

5.  Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors:  M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

6.  Production and purification of cholera toxin.

Authors:  J J Mekalanos
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

7.  H-2-unrestricted adjuvant effect of cholera toxin B subunit on murine antibody responses to influenza virus haemagglutinin.

Authors:  Y Hirabayashi; S I Tamura; Y Suzuki; T Nagamine; C Aizawa; K Shimada; T Kurata
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

8.  Cloning, sequencing, and expression of a gene encoding a 100-kilodalton mosquitocidal toxin from Bacillus sphaericus SSII-1.

Authors:  T Thanabalu; J Hindley; J Jackson-Yap; C Berry
Journal:  J Bacteriol       Date:  1991-05       Impact factor: 3.490

9.  Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin.

Authors:  J T Barbieri; D Armellini; J Molkentin; R Rappuoli
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

10.  Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli.

Authors:  T K Sixma; S E Pronk; K H Kalk; E S Wartna; B A van Zanten; B Witholt; W G Hol
Journal:  Nature       Date:  1991-05-30       Impact factor: 49.962

View more
  37 in total

1.  New method to generate enzymatically deficient Clostridium difficile toxin B as an antigen for immunization.

Authors:  H Genth; J Selzer; C Busch; J Dumbach; F Hofmann; K Aktories; I Just
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

2.  Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin.

Authors:  C Magagnoli; R Manetti; M R Fontana; V Giannelli; M M Giuliani; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

3.  Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin.

Authors:  L de Haan; W R Verweij; I K Feil; T H Lijnema; W G Hol; E Agsteribbe; J Wilschut
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

4.  Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.

Authors:  G Douce; M Fontana; M Pizza; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

5.  Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30.

Authors:  D J Bast; J Sandhu; N Hozumi; B Barber; J Brunton
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

6.  Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit.

Authors:  M R Fontana; R Manetti; V Giannelli; C Magagnoli; A Marchini; R Olivieri; M Domenighini; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

7.  The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies.

Authors:  Marzia Monica Giuliani; Laura Santini; Brunella Brunelli; Alessia Biolchi; Beatrice Aricò; Federica Di Marcello; Elena Cartocci; Maurizio Comanducci; Vega Masignani; Luisa Lozzi; Silvana Savino; Maria Scarselli; Rino Rappuoli; Mariagrazia Pizza
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

8.  A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.

Authors:  Yukari Hagiwara; Yuki I Kawamura; Kosuke Kataoka; Bibi Rahima; Raymond J Jackson; Katsuhiro Komase; Taeko Dohi; Prosper N Boyaka; Yoshifumi Takeda; Hiroshi Kiyono; Jerry R McGhee; Kohtaro Fujihashi
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

9.  Nasal vaccination with the 40-kilodalton outer membrane protein of Porphyromonas gingivalis and a nontoxic chimeric enterotoxin adjuvant induces long-term protective immunity with reduced levels of immunoglobulin E antibodies.

Authors:  Fumiki Momoi; Tomomi Hashizume; Tomoko Kurita-Ochiai; Yoshikazu Yuki; Hiroshi Kiyono; Masafumi Yamamoto
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

10.  Eradication of chronic Helicobacter pylori infection by therapeutic vaccination.

Authors:  J E Crabtree
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.